Last $54.89 USD
Change Today -0.355 / -0.64%
Volume 3.5M
MYL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 8:10 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

mylan inc (MYL) Key Developments

Mylan Inc. Loses Patent Fight over MS Drug

The Supreme Court ruled against Mylan Inc. and other firms in their challenge of Teva Pharmaceutical Industries' patents for a blockbuster multiple sclerosis drug. The justices ruled 7-2 that a federal appeals court wrongly overturned five of Teva's patents for the drug Copaxone, which generates about $4 billion in annual sales for Teva. The majority told a lower court to reconsider a ruling invalidating the patents. The decision allows the Israel-based company to keep its exclusive rights to Copaxone until September, delaying generic competition from Mylan and the other companies. And it gives Teva more time to shift patients to a longer acting version that won't face competition until 2030. Teva had argued that the U.S. Court of Appeals for the Federal Circuit should not have second-guessed factual findings made by a federal district court that had ruled in Teva's favor. The Supreme Court agreed that the Federal Circuit should have deferred to factual findings made by the lower court. The other companies involved in the case are Momenta Pharmaceuticals Inc. and Sandoz Inc.

Mylan Reportedly In Talks With Famy Care

Mylan, Inc. (NasdaqGS:MYL) is in advanced discussions to acquire Famy Care Ltd. from JP Taparia family in a deal estimated at over $500 million, The Times of India reported citing people familiar with the matter. JP Taparia family had appointed Credit Suisse AG to explore strategic options for Famy Care Ltd. Bain Capital, LLC and Advent International Corporation were also the potential suitors. An emailed query to Mylan, Inc.'s spokesperson Nina Devlin remained unanswered at the time of going to press. An external spokesperson for Famy Care Ltd. said that the company has retained Credit Suisse AG but nothing has been finalized yet. And any talk about a deal currently is in the realm of speculation.

Mylan Inc. Launches Generic Version of Hepatitis B Virus Infection Drug in U.S

Mylan Inc. announced the U.S. launch of its Lamivudine tablets, 100 mg, which are indicated to treat chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation. Lamivudine tablets are the generic version of GlaxoSmithKline's (GSK) Epivir-HBV.

Mylan Inc. Announces the U.S. Launch of 100 mg - Lamivudine Tablets

Mylan Inc. announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's Epivir-HBV. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation.

Mylan Mulls Acquisitions

Mylan, Inc. (NasdaqGS:MYL) is looking for acquisitions. Chief Executive Officer, Heather Bresch stated, “So taking now the significant financial flexibility we believe just continues to add that momentum and really accelerates some of these growth opportunities both from an organic, as well as an acquisition perspective.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $54.89 USD -0.355

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Omnicare Inc $76.05 USD +0.55
Perrigo Co PLC $154.00 USD +0.49
UCB SA €69.25 EUR -0.96
WW Grainger Inc $235.92 USD +4.88
WESCO International Inc $67.22 USD +0.69
View Industry Companies
 

Industry Analysis

MYL

Industry Average

Valuation MYL Industry Range
Price/Earnings 23.8x
Price/Sales 2.8x
Price/Book 6.1x
Price/Cash Flow 22.5x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.